CareDx (CDNA) Earnings Date & Reports

Key Takeaways

• Revenue beat: CareDx delivered second-quarter revenue of $132 million, up 52% year-over-year and well above the consensus estimate of approximately $114 million.
• Earnings outperformance: Non-GAAP diluted earnings per share (EPS) came in at $0.37, significantly exceeding the analyst consensus of $0.23.
• Testing services drove growth: Testing Services revenue jumped 61% year-over-year to $100 million, supported by a 17% increase in testing volume to approximately 58,000 tests.
• Full-year guidance raised: Management lifted its 2026 revenue outlook to a range of $490 million to $500 million, up from the prior range of $447 million to $465 million, and raised adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance to $66 million to $78 million.
• Strategic transformation: The quarter was marked by the completed divestiture of the Lab Products business to Eurobio Scientific and the acquisition of Naveris, sharpening CareDx's focus on transplant, specialty oncology, and cell therapy diagnostics.
• Medicare clarity secured: CMS (Centers for Medicare & Medicaid Services) finalized its Medicare coverage policy for AlloSure and AlloMap testing, removing a key reimbursement overhang.

Earnings Context and Why It Matters

CareDx's second-quarter 2026 results represent a defining moment for the precision medicine diagnostics company. Coming just two weeks after CMS finalized favorable Medicare coverage for its flagship transplant surveillance tests, this earnings report was the first opportunity for management to translate policy clarity into concrete financial guidance. The quarter also reflected the simultaneous closing of two transformative transactions — the sale of the Lab Products business and the acquisition of Naveris — reshaping CareDx into a more focused entity centered on transplant, specialty oncology, and cell therapy. For investors, these results provide a critical checkpoint on whether the company's growth trajectory, profitability path, and strategic repositioning can sustain the stock's remarkable rally from its 52-week low of $11.26.

Reported Results

CareDx reported total revenue of $132 million for the second quarter ended June 30, 2026, representing a 52% increase from $87 million in the same period a year ago and comfortably surpassing the consensus analyst estimate of approximately $114 million. Testing Services revenue, the company's core growth engine, climbed 61% year-over-year to $100 million, driven by a 17% rise in testing volume to roughly 58,000 tests and an average revenue per test of approximately $1,720, which included $16 million in revenue recognized from tests performed in prior periods. Excluding that prior-period component, Testing Services revenue still grew approximately 28% year-over-year.

Patient and Digital Solutions revenue rose 50% to $19 million, reflecting continued expansion in CareDx Pharmacy services and digital health adoption. Lab Product revenue increased 8% to $13 million in its final full quarter under CareDx ownership, as the divestiture to Eurobio Scientific closed on June 30, 2026.

On the bottom line, GAAP (Generally Accepted Accounting Principles) net income reached $111 million, compared to a GAAP net loss of $9 million in the prior-year quarter. This figure included a $113 million gain on the sale of the Lab Products business. Non-GAAP net income, which excludes that gain and other items, was $20 million, up from $6 million a year ago, yielding non-GAAP diluted EPS of $0.37 — comfortably above the $0.23 consensus. Adjusted EBITDA expanded to $25 million from $5 million in the second quarter of 2025, and operating cash flow came in at $31 million.

AI Screener

For investors looking to identify opportunities in the fast-moving diagnostics and healthcare technology space, Tickeron's AI Screener offers a powerful, AI-driven platform designed to streamline the stock discovery process. The AI Screener allows traders and investors to filter thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated signals. By surfacing breakout candidates, trending stocks, and trade ideas based on real-time data and pattern recognition, the tool helps users cut through market noise more efficiently than manual screening. Whether you are monitoring earnings-driven movers like CareDx or seeking new ideas across sectors, the AI Screener can help you stay ahead of the market.

Market Reaction and Investor Sentiment

CareDx shares responded positively to the second-quarter results, with the stock closing at $38.16 following the earnings release, according to Investing.com data — a notable gain from the July 29 close of $35.41. The stock had already surged more than 20% in mid-July following CMS's finalization of the Medicare coverage policy, and the strong earnings beat combined with raised full-year guidance reinforced bullish sentiment. Heading into the print, analyst ratings were split between Buy and Hold, with BTIG notably raising its price target from $28 to $45 following the Medicare decision. The company's ability to deliver revenue and EPS well above consensus — despite some concerns about a potential sequential dip from the first quarter — appeared to validate the thesis that transplant testing demand and favorable reimbursement dynamics remain powerful tailwinds. The raised full-year guidance, now calling for up to $500 million in revenue, exceeded the prevailing analyst consensus of approximately $456 million and signaled management's confidence in sustained momentum through the second half of 2026.

Forward Outlook and Key Factors to Monitor

Looking ahead, CareDx enters the second half of 2026 with considerable operational momentum and a clearer regulatory landscape. The finalized Medicare Local Coverage Determination (LCD), which takes effect August 30, establishes test-frequency limits that analysts have described as "generous" — allowing up to six AlloSure Kidney surveillance tests in the first year post-transplant and up to four annually in years two and three. Since kidney patients currently average approximately three to four tests in the first year, these limits provide a meaningful runway for volume expansion without immediately constraining growth.

Investors should closely monitor the integration of the Naveris acquisition, which adds NavDx testing for HPV-associated cancers and expands CareDx's oncology footprint. The successful ramp of this new revenue stream, alongside the continued progress of pipeline programs such as AlloHeme, will be important indicators of the company's ability to diversify beyond transplant testing. The AlloHeme program, which targets blood cancer monitoring, recently reached a milestone with the submission of a clinical validation manuscript and continued progress toward CLIA (Clinical Laboratory Improvement Amendments) readiness.

On the financial side, profitability trends remain a central focus. The second quarter demonstrated meaningful operating leverage, with adjusted EBITDA growing fivefold year-over-year. The raised adjusted EBITDA guidance of $66 million to $78 million for full-year 2026 signals management's expectation that margin expansion can continue alongside revenue growth. However, with the Lab Products business now divested and Naveris integration costs still unfolding, investors will want to track whether non-GAAP profitability can be sustained and expanded on a quarterly basis. Reimbursement dynamics, payer behavior beyond Medicare, and the pace of transplant procedure volumes across the United States will also remain key external variables shaping CareDx's trajectory through year-end and into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations